该项收购完成后,Cambrex公司将获得Avista公司包括从原料药、药品开发、环化核苷酸制造,到独立分析、微生物测验以及固态科学等多项服务,同时将Avista的4个制药站点纳入其生...查看全文
琬麟2015-02-07 09:21
$凯姆布雷克斯(CBM)$ EAST RUTHERFORD, N.J., Feb. 6, 2015 /PRNewswire/ -- Cambrex Corporation (NYSE: CBM, "Cambrex") is pleased to announce that it has initiated the second significant expansion of its Charles City, Iowa facility in less than three years. Strong continu...查看全文
$凯姆布雷克斯(CBM)$ 8-K - Current report Filed: 2019-08-08 AccNo: 0001193125-19-215628 Size: 1 MBItem 1.01: Entry into a Material Definitive AgreementItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Ar...
$凯姆布雷克斯(CBM)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-08-08 AccNo: 0001193125-19-215629 Size: 926 KB 网页链接
$凯姆布雷克斯(CBM)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2019-08-07 AccNo: 0001564590-19-029675 Size: 11 MB 网页链接
$凯姆布雷克斯(CBM)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-08-07 AccNo: 0001193125-19-215446 Size: 25 KB 网页链接
$凯姆布雷克斯(CBM)$ DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material Filed: 2019-08-07 AccNo: 0001193125-19-215447 Size: 27 KB 网页链接
$凯姆布雷克斯(CBM)$ 美东时间 2019-08-09 盘前 披露财报,预期EPS 0.36 网页链接
$凯姆布雷克斯(CBM)$ 8-K - Current report Filed: 2019-05-02 AccNo: 0001564590-19-015026 Size: 1 MBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$凯姆布雷克斯(CBM)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2019-05-02 AccNo: 0001564590-19-015031 Size: 8 MB 网页链接
$凯姆布雷克斯(CBM)$ 美东时间 2019-05-02 盘前 披露财报,预期EPS 0.21 网页链接
$凯姆布雷克斯(CBM)$ 8-K - Current report Filed: 2019-04-25 AccNo: 0001564590-19-013036 Size: 97 KBItem 5.07: Submission of Matters to a Vote of Security Holders 网页链接